Wall Street analyst price targets, ratings consensus & upside potential · Updated Feb 28, 2026
Last 12 months price action with 12-month analyst target path
As of March 2, 2026, BridgeBio Pharma, Inc. (BBIO) has a Wall Street consensus price target of $98.92, based on estimates from 26 covering analysts. With the stock currently trading at $66.48, this represents a potential upside of +48.8%. The company has a market capitalization of $12.95B.
Analyst price targets range from a low of $83.00 to a high of $157.00, representing a 75% spread in expectations. The median target of $96.00 aligns closely with the consensus average. The wide target spread reflects significant disagreement on fair value.
The current analyst consensus rating is Buy, with 25 analysts rating the stock as a Buy or Strong Buy,1 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, BBIO trades at a trailing P/E of -17.5x. Analysts expect EPS to grow +54.7% over the next year.
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorSee our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationSee how BBIO stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonThe consensus Wall Street price target for BBIO is $98.92, representing 48.8% upside from the current price of $66.48. With 26 analysts covering the stock, this strong upside suggests significant value not yet reflected in today's share price.
BBIO has a consensus rating of "Buy" based on 26 Wall Street analysts. The rating breakdown is predominantly bullish, with 25 Buy/Strong Buy ratings. The consensus 12-month price target of $98.92 implies 48.8% upside from current levels.
BBIO's current price is $66.48 with a consensus target of $98.92 (48.8% implied move). Analyst estimates suggest the stock is undervalued at current levels.
The most bullish Wall Street analyst has a price target of $157 for BBIO, while the most conservative target is $83. The consensus of $98.92 represents the median expectation. These targets typically reflect 12-month expectations.
BBIO is heavily covered by Wall Street, with 26 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 25 have Buy ratings, 1 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month BBIO stock forecast based on 26 Wall Street analysts shows a consensus price target of $98.92, with estimates ranging from $83 (bear case) to $157 (bull case). The median consensus rating is "Buy".
Wall Street analysts are very optimistic on BBIO, with a "Buy" consensus rating and $98.92 price target (48.8% upside). 25 of 26 analysts rate it Buy or Strong Buy. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
BBIO analyst price targets range from $83 to $157, a 75% wide spread indicating significant analyst disagreement. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $98.92 consensus represents the middle ground.